Arcus Biosciences to present new ARC-20 casdatifan data in kidney cancer at Oct. 20 investor event

Arcus Biosciences set an in-person investor event for Oct. 20, 2026, to disclose new ARC-20 study data for casdatifan in kidney cancer.

Results have not yet been presented; the update will cover performance across first-line combinations, a second-line combination, and late-line monotherapy.

Management will frame whether casdatifan can serve as a backbone therapy across treatment lines, a key determinant of commercial positioning.

Safety readouts are expected to support a first-line registrational trial planned for the fourth quarter of 2026.

Updated evidence from a second-line regimen will align with a separate registrational study targeted to finish enrollment by end-2026.